Q3 EPS Forecast for Satellos Bioscience Lifted by Analyst

Satellos Bioscience Inc. (NASDAQ:MSLE) – Analysts at HC Wainwright upped their Q3 2026 earnings estimates for shares of Satellos Bioscience in a note issued to investors on Monday, May 18th. HC Wainwright analyst A. He now expects that the company will earn ($0.36) per share for the quarter, up from their previous estimate of ($0.37). HC Wainwright has a “Buy” rating and a $11.00 price objective on the stock. The consensus estimate for Satellos Bioscience’s current full-year earnings is ($2.20) per share. HC Wainwright also issued estimates for Satellos Bioscience’s Q4 2026 earnings at ($0.36) EPS, FY2026 earnings at ($1.60) EPS, Q1 2027 earnings at ($0.39) EPS, Q2 2027 earnings at ($0.42) EPS, Q4 2027 earnings at ($0.49) EPS, FY2027 earnings at ($1.76) EPS, FY2028 earnings at ($1.87) EPS and FY2029 earnings at ($1.16) EPS.

Satellos Bioscience (NASDAQ:MSLE) last posted its earnings results on Friday, May 15th. The company reported ($0.53) EPS for the quarter, missing the consensus estimate of ($0.51) by ($0.02).

MSLE has been the subject of several other research reports. Guggenheim began coverage on shares of Satellos Bioscience in a research report on Tuesday, April 28th. They issued a “buy” rating and a $23.00 target price for the company. Leerink Partners began coverage on shares of Satellos Bioscience in a research report on Monday, April 6th. They issued an “outperform” rating and a $20.00 target price for the company. Cantor Fitzgerald began coverage on shares of Satellos Bioscience in a research report on Wednesday, March 11th. They issued an “overweight” rating for the company. Wall Street Zen upgraded shares of Satellos Bioscience from a “strong sell” rating to a “sell” rating in a research report on Saturday. Finally, Zacks Research upgraded shares of Satellos Bioscience to a “hold” rating in a research report on Tuesday, February 10th. Four research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Satellos Bioscience has an average rating of “Moderate Buy” and a consensus target price of $18.00.

Satellos Bioscience Trading Down 2.2%

NASDAQ MSLE opened at $6.99 on Wednesday. Satellos Bioscience has a 52 week low of $4.53 and a 52 week high of $13.39. The company has a market cap of $145.60 million, a PE ratio of -4.37 and a beta of 1.60. The stock has a 50-day moving average price of $7.31.

Trending Headlines about Satellos Bioscience

Here are the key news stories impacting Satellos Bioscience this week:

• Positive Sentiment: HC Wainwright reaffirmed a Buy rating on Satellos Bioscience and maintained an $11 price target, implying substantial upside from recent trading levels. Article Title
• Positive Sentiment: The analyst raised earnings estimates for several future periods, including Q3 2026, Q4 2026, Q1 2027, Q2 2027, Q4 2027, FY2027, FY2028, FY2029 and FY2030, indicating improving long-term outlook. Article Title
• Neutral Sentiment: The company remains unprofitable, and the consensus estimate for the current full year is still a loss of $2.20 per share, so investors are likely weighing future growth potential against ongoing deficits.
• Negative Sentiment: HC Wainwright cut its FY2026 EPS estimate to a larger loss of ($1.60) from ($1.45), suggesting near-term earnings pressure remains. Article Title

About Satellos Bioscience

Satellos Bioscience Inc is a regenerative medicine company dedicated to developing novel therapeutics which stimulate or restore muscle regeneration in severe disorders. The company’s lead program is focused on developing an oral therapeutic drug for Duchenne muscular dystrophy. Satellos Bioscience Inc, formerly known as iCo Therapeutics Inc, is based in Toronto, Ontario.